299 results on '"Gatselis, Nikolaos K"'
Search Results
2. PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality
3. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
4. Osteonecrosis risk after steroids-related treatment of COVID-19 is not negligible: A cross sectional study
5. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
6. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group
7. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease
8. Autoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis
9. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial
10. PNPLA3 I148M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality
11. Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis
12. PSC-AIH Overlap
13. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe
14. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19
15. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases
16. NAFLD and autoimmune hepatitis: Do not judge a book by its cover
17. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis
18. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
19. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
20. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool
21. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases
22. Radiologic Features of T10 Paravertebral Muscle Sarcopenia: Prognostic Factors in COVID-19
23. Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from two tertiary Greek centers
24. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece
25. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis
26. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
27. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival
28. Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
29. Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis
30. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
31. Autoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis
32. Liver-transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
33. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
34. Recent advances in the diagnosis and management of autoimmune hepatitis
35. P09 Long-term obeticholic acid (OCA) for Primary Biliary Cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
36. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
37. Hepcidin as a Sensitive and Treatment-Responsive Acute-Phase Marker in Patients with Bacteremia: A Pilot Study
38. Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
39. Liver-transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
40. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
41. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
42. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases
43. Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients
44. Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution
45. First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients
46. Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE Trial
47. Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis
48. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
49. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease
50. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.